US Trial Begins for Prostate Cancer Therapy by Syncromune
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
US Trial Begins for Prostate Cancer Therapy by Syncromune
By Frank Parlato He Took It to Mexico. Now It’s Back in the U.S. A Phase 2 clinical trial has begun enrolling patients in the United States for an experimental immunotherapy designed to treat metastatic prostate cancer, according to its developer, Syncromune, Inc. The trial would test an idea both simple and unsettling: freeze part of the tumor, then poison it from within by injecting four immune-activating drugs into it. The rationale is that f…
US Trial Begins for Prostate Cancer Therapy Developed by Syncromune’s Dr. Jason Williams
He Took It to Mexico. Now It’s Back in the U.S. A Phase 2 clinical trial has begun enrolling patients in the United States for an experimental immunotherapy designed to treat metastatic prostate cancer, according to its developer, Syncromune, Inc. The trial would test an idea both simple and unsettling: freeze part of the tumor, then poison it from within by injecting four immune-activating drugs into it. The rationale is that freezing a tumor s…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
